Bioactive glass nanoparticles (BGN) are promising materials for a number of biomedical applications. Many parameters related to the synthesis of BGN using sol–gel methods can affect their characteristics. In this study, the influence of timing of calcium nitrate (calcium precursor) addition during processing on BGN characteristics was investigated. The results showed that the addition timing could affect the morphology, dispersity and composition of BGN. With delayed addition of calcium nitrate, larger, more regular and better dispersed BGN could be synthesized while the gap between nominal and actual compositions of BGN was widened. However, the addition timing had no significant influence on structural characteristics, as BGN with different addition-timing of calcium nitrate exhibited similar infrared spectra and amorphous nature. The results also suggested that monodispersed BGN could be synthesized by carefully controlling the addition of calcium nitrate. The synthesized monodispersed BGN could release Si and Ca ions continuously for up to at least 14 days. They also showed in vitro bioactivity and non-cytotoxicity towards rat bone marrow-derived mesenchymal stem cells (rBMSCs). In conclusion, the timing of calcium precursor addition is an essential parameter to be considered when producing BGN which should exhibit monodisperse characteristics for biomedical applications.

In this study, we report the synthesis of gold-coated iron oxide nanoparticles capped with polyvinylpyrrolidone (Fe@Au NPs). The as-synthesized nanoparticles (NPs) exhibited good stability in aqueous media and excellent features as contrast agents (CA) for both magnetic resonance imaging (MRI) and X-ray computed tomography (CT). Additionally, due to the presence of the local surface plasmon resonances of gold, the NPs showed exploitable “light-to-heat” conversion ability in the near-infrared (NIR) region, a key attribute for effective photothermal therapies (PTT). In vitro experiments revealed biocompatibility as well as excellent efficiency in killing glioblastoma cells via PTT. The in vivo nontoxicity of the NPs was demonstrated using zebrafish embryos as an intermediate step between cells and rodent models. To warrant that an effective therapeutic dose was achieved inside the tumor, both intratumoral and intravenous routes were screened in rodent models by MRI and CT. The pharmacokinetics and biodistribution confirmed the multimodal imaging CA capabilities of the Fe@AuNPs and revealed constraints of the intravenous route for tumor targeting, dictating intratumoral administration for therapeutic applications. Finally, Fe@Au NPs were successfully used for an in vivo proof of concept of imaging-guided focused PTT against glioblastoma multiforme in a mouse model.